The Claim
After adjustment for mean intraocular pressure, there is no statistically significant difference in visual field progression between patients treated with the Hydrus Microstent and those treated with cataract surgery alone, indicating that the device's effect on visual field progression is mediated by intraocular pressure reduction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When intraocular pressure is accounted for, the Hydrus Microstent does not produce a different rate of visual field decline compared to cataract surgery alone, meaning its impact on vision preservation is due to lowering eye pressure.
See the scientific wording
After adjusting for washed-out mean intraocular pressure, the difference in visual field progression between patients receiving the Hydrus Microstent and those receiving cataract surgery alone is no longer statistically significant, suggesting that the device’s primary benefit is mediated through long-term IOP reduction rather than other mechanisms.
Lower pressure inside the eye reduces stress on the optic nerve fibers, which prevents them from breaking down over time and preserves vision.
What the research says
1 studyStudy: Effect of intraocular pressure control on visual field progression in the HORIZON trial.
The Hydrus stent helps slow vision loss mainly because it lowers eye pressure over time — when researchers accounted for this pressure drop, the stent didn’t seem to help any more than surgery alone.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.